Fluocinolone acetonide intravitreal implant (Iluvien®): In diabetic macular oedema

Drugs

Volumn 73, Issue 2, 2013, Pages 187-193

  Sanford, Mark ^a  

^a Adis 41 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; FLUOCINOLONE ACETONIDE; INTRAOCULAR PRESSURE LOWERING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CATARACT; CATARACT EXTRACTION; CONJUNCTIVAL HYPEREMIA; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISCHARGE; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; IRIS DISEASE; LASER COAGULATION; OCULAR FIBROSIS; OCULAR PRURITUS; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA BLOOD VESSEL OCCLUSION; RETINA EXUDATE; RETINA MACULOPATHY; SCLERA DISEASE; SHAM PROCEDURE; SIDE EFFECT; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

DIABETIC RETINOPATHY; DRUG IMPLANTS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; VITREOUS BODY;

EID: 84877050297     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0010-x     Document Type: Article

References (14)

1. Blumenkranz MS. Optimal current and future treatments for diabetic macular oedema. Eye. 2010;24(3):428-34.
2. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64.
3. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32.
4. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27(4):530-43.
5. Bausch & Lomb Inc. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use: US prescribing information; 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021737s019.pdf. Accessed 21 November 2012.
6. Pearson PA, Cornstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled trial. Ophthalmology. 2011;118(8):1580-7.
7. Medicine and Healthcare products Regulatory Agency. Iluvien 190 micrograms intravitreal implant in applicator: summary of product characteristics; 2012. http://www.mhra.gov.uk/home/groups/spcpil/documents/ spcpil/con1342494701591.pdf. Accessed 19 November 2012.
8. Grover D, Li TJ, Chong CCW. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008(1):CD005656.
9. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002;85(2):61-75.
10. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20:407-16.
11. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Opthalmology. 2012;. doi: 10.1016/j.optha.2012. 09.014.
12. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-35.e2.
13. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-32.
14. Alimera Sciences Inc. Fluocinolone acetonide in diabetic macular edema (FAME) extension study. 2012. http://clinicaltrials.gov/ct2/results?term= NCT01304706. Accessed 19 November 2012.